Navigation Links
In First- and Second-Line Treatment of Clostridium Difficile Infection, Nearly 70 Percent of Surveyed Infectious Disease Specialists and Internists Will Use Fidaxomicin and Nearly Half Will Use CDA1/CDB1

WALTHAM, Mass., Aug. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in first- and second-line treatment of Clostridium difficile infection (CDI), nearly 70 percent of surveyed infectious disease specialists and internists will use Optimer's fidaxomicin and nearly half will use Medarex/Merck's CDA1 and CDB1, one year after the launch of these agents. The lower recurrent/relapse rate associated with fidaxomicin and CDA1/CDB1 is the most influential attribute surveyed clinicians cite in their decisions to prescribe these emerging agents for CDI.

The new Physician & Payer Forum report entitled Hospital Anti-Infectives: Insights on the Uptake and Formulary Inclusion of Emerging Antibiotics and Antifungals—A Survey of Infectious Disease Specialists, Internists and P&T Committee Members finds that fidaxomicin and, to a higher degree, CDA1/CDB1, will also see robust uptake by surveyed clinicians for the treatment of recurrent CDI. The report also finds that approximately two-thirds of pharmacy and therapeutics committee (P&T) members expect to include fidaxomicin and CDA1/CDB1 on their hospital's formulary.

Fidaxomicin and CDA1/CDB1 would provide much needed options for the treatment of CDI as the only currently available agents in this indication are Pfizer's metronidazole (generically available) and ViroPharma's Vancocin. According to the report, unmet need for novel anti-infectives is shifting away from methicillin-resistant Staphylococcus aureus (MRSA) to CDI and gram-negative infections.

"In addition to MRSA, infectious disease specialists report a rise in CDI and gram-negative infections," said Decision Resources Therapeutic Area Director Danielle Drayton, Ph.D. "Over the past 12 months, 82 percent of surveyed infectious disease specialists observed an increase in the incidence of ESBL-producing enterobacteriaceae while more than half of surveyed clinicians also point to an increase in the incidence of CDI and MRSA. Drugs that target key gram-negative pathogens such as Pseudomonas aeruginosa and ESBL-producing enterobacteriaceae and Clostridium difficile stand to address a key unmet need and will capitalize on untapped market opportunities."

The report also finds that Forest/AstraZeneca/Takeda's ceftaroline and Trius's torezolid are the two late-stage emerging therapies that are most likely to gain formulary inclusion, according to surveyed P&T committee members. Seventy one percent of surveyed P&T committee members expect torezolid to be on formulary and 62 percent expect ceftaroline to be on formulary.

Hospital Anti-Infectives: Insights on the Uptake and Formulary Inclusion of Emerging Antibiotics and Antifungals—A Survey of Infectious Disease Specialists, Internists and P&T Committee Members is based on a U.S. survey of 51 infectious disease specialists, 52 internal medicine specialists and 21 infectious disease specialists who sit on their hospital's P&T committee.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or

registered trademarks of their respective holders.

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
2. WuXi PharmaTech Announces First-Quarter 2010 Results
3. WuXi PharmaTech Schedules First-Quarter 2010 Earnings Release
4. Ligon Discovery and Lycera Collaborate to Develop First-in-Class Drugs for Immune Disorders
5. Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
6. VELOCITY Broadcasting Introduces HD2PC(SM), the First-Ever High-Definition Direct to PC Delivery of Private Broadcast Television
7. JDRF Forms Partnership With Animas to Develop First-Generation Automated System for Managing Type 1 Diabetes
8. Mylan Confirms First-to-File Patent Challenge Relating to Vytorin(R) Cholesterol Medication
9. Lilly Declares First-Quarter 2010 Dividend
10. FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology
11. CPG Implements First-Ever Agile PLM Release 9.3 at Avema Pharma Solutions
Post Your Comments:
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):